Teva reaches USD 35 million settlement in QVAR antitrust case
Teva Pharmaceuticals USA, Inc., and affiliated companies have agreed to pay USD 35 million to resolve a class action lawsuit alleging that the drugmaker delayed generic competition for its asthma inhaler, QVAR




















